Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

378

10.17650/1994-4098-2008-0-4-37-42

MAMMOLOGY. PHARMACOTHERAPY

МАММОЛОГИЯ. ФАРМАКОТЕРАПИЯ

Potentialities of adjuvant endocrine therapy for breast cancer (Part II)

ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть II*)

Dobrovolskaya

N. Yu.

Добровольская

Н. Ю.

Russian Federation

Vvoznyi

E. K.

Ввозный

Э. К.

Russian Federation

Bychkov

Yu. M.

Бычков

Ю. М.

Russian Federation

ФГУ Российский научный центр рентгенорадиологии Росздрава, Москва

17112008

37421709201417092014

2008

https://ojrs.abvpress.ru/ojrs/article/view/378

Potentialities of adjuvant endocrine therapy for breast cancer (Part II)

ВОЗМОЖНОСТИ АДЪЮВАНТНОЙ ЭНДОКРИННОЙ ТЕРАПИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ (часть II*)

8. Cuzick J., Powles T., Veronesi U. et al. Overview of the main outcomes in breast- cancer prevention trials. Lancet 2003;361:296—300.

Cuzick J., Powles T., Veronesi U. et al. Overview of the main outcomes in breast- cancer prevention trials. Lancet 2003;361:296—300.

9. Braithwaite R.S., Chlebowski R.T., Lau J. et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937—47.

Braithwaite R.S., Chlebowski R.T., Lau J. et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937—47.

10. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007;153:182—8.

Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007;153:182—8.

11. Wysowski D.K., Honig S., Beitz J. Uterine sarcoma associated with tamox- ifen use. N Engl J Med 2002;346:1832—3.

Wysowski D.K., Honig S., Beitz J. Uterine sarcoma associated with tamox- ifen use. N Engl J Med 2002;346:1832—3.

12. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast can- cer. Lancet 2005;365:60—2.

ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast can- cer. Lancet 2005;365:60—2.

13. Coates A.S., Keshaviah A., Thurlimann B. et al. Five years of letro- zole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1— 98. J Clin Oncol 2007;25:486—92.

Coates A.S., Keshaviah A., Thurlimann B. et al. Five years of letro- zole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1— 98. J Clin Oncol 2007;25:486—92.

14. Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2—3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised con- trolled trial. Lancet 2007;369:559—70.

Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2—3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised con- trolled trial. Lancet 2007;369:559—70.

15. Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619—29.

Winer E.P., Hudis C., Burstein H.J. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619—29.

16. The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131—9.

The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131—9.

10.

17. The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802—10.

The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802—10.

11.

18. Goldhirsch A., Wood W., Gelber R. et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133—44.

Goldhirsch A., Wood W., Gelber R. et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133—44.

12.

19. Viale G., Regan M.M., Maiorano E. et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a random- ized trial comparing letrozole and tamox- ifen adjuvant therapy for postmenopausal early breast cancer: BIG 1—98. J Clin Oncol 2007;25:3846—52.

Viale G., Regan M.M., Maiorano E. et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a random- ized trial comparing letrozole and tamox- ifen adjuvant therapy for postmenopausal early breast cancer: BIG 1—98. J Clin Oncol 2007;25:3846—52.

13.

20. Dowsett M., Allred D.C., on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expres- sion and Her-2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006;100 (suppl 1):21 (abstr 48).

Dowsett M., Allred D.C., on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expres- sion and Her-2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006;100 (suppl 1):21 (abstr 48).

14.

21. Cox D.R. Regression models and life tables. J R Stat Soc 1972;34:187—220.

Cox D.R. Regression models and life tables. J R Stat Soc 1972;34:187—220.

15.

22. Jones M.C., Wand M.P. Kernel smoothing. Boca Raton, FL: CRC Press; 1994.

Jones M.C., Wand M.P. Kernel smoothing. Boca Raton, FL: CRC Press; 1994.

16.

23. Food and Drug Administration (COSTART). The coding symbols for thesaurus of adverse reaction terms, 5th ed; 1995.

Food and Drug Administration (COSTART). The coding symbols for thesaurus of adverse reaction terms, 5th ed; 1995.

17.

24. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H. et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952—60.

Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H. et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952—60.

18.

25. The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633—43.

The ATAC Trialists’ Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633—43.

19.

26. Coleman R.E., on behalf of the ATAC Trialists’ Group. Effect of anastro- zole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;24:18. Abstr 511.

Coleman R.E., on behalf of the ATAC Trialists’ Group. Effect of anastro- zole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Proc ASCO 2006;24:18. Abstr 511.

20.

27. Eastell R., Adams J.E., Coleman R. et al. Effect of anastrozole on bone min- eral density: 5-year results from the ATAC trial (18233230). J Clin Oncol 2008;26(7):1051—7.

Eastell R., Adams J.E., Coleman R. et al. Effect of anastrozole on bone min- eral density: 5-year results from the ATAC trial (18233230). J Clin Oncol 2008;26(7):1051—7.

21.

28. Eastell R., Van Poznack C., Hannon R.A. et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronat E) study: 12-month analysis. J Bone Miner Res 2007;22(suppl 1):113.

Eastell R., Van Poznack C., Hannon R.A. et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronat E) study: 12-month analysis. J Bone Miner Res 2007;22(suppl 1):113.

22.

29. Singh S., Cuzick J., Edward R. et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). Breast Cancer Res Treat 2007;106(suppl 1):9. Abstr 28.

Singh S., Cuzick J., Edward R. et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Prevention Study (IBIS-II). Breast Cancer Res Treat 2007;106(suppl 1):9. Abstr 28.

23.

30. Fisher B., Costantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.

Fisher B., Costantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.

24.

31. Jakesz R., Kaufmann M., Gnant M. et al. Benefits of switching post- menopausal women with hormone-sensi- tive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: com- bined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Conference; 2004. Abstr. 2.

Jakesz R., Kaufmann M., Gnant M. et al. Benefits of switching post- menopausal women with hormone-sensi- tive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: com- bined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Conference; 2004. Abstr. 2.